{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidllq3525rts5wdupq35xcv3zmzivtu2yozvorjto3qg3mz65dpvy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjnfq4xfzpr2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibv2cgodtuhcx5z6npuciienu7qxe754otododoc64xdglydjw4rq"
    },
    "mimeType": "image/jpeg",
    "size": 746396
  },
  "path": "/news/2026-04-line-therapy-antitumor-patients-advanced.html",
  "publishedAt": "2026-04-16T17:20:06.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted treatment alternative to chemotherapy, according to researchers at The University of Texas MD Anderson Cancer Center.",
  "title": "First-line targeted therapy shows antitumor activity in patients with advanced lung cancer"
}